JP-1366 + naproxen

JP-1366 + naproxen is a fixed-dose combination of two drugs: - **JP-1366 (zastaprazan):** A novel, fast-acting potassium-competitive acid blocker (P-CAB) that selectively and potently inhibits gastric H+/K+-ATPase, thereby suppressing gastric acid secretion. It is indicated for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD), peptic ulcers, and erosive esophagitis. Unlike traditional proton pump inhibitors (PPIs), it acts directly on the proton pump without requiring activation by gastric acid and is not affected by CYP2C19 genetic polymorphisms[1][2][8]. - **Naproxen:** A nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation associated with conditions like arthritis, ankylosing spondylitis, tendinitis, bursitis, gout, or menstrual cramps[4][9]. NSAIDs like naproxen are commonly associated with gastrointestinal side effects such as ulcers. The rationale for combining these agents would be to provide anti-inflammatory/analgesic benefits from naproxen while reducing gastrointestinal risks through potent acid suppression from JP-1366. This approach mirrors other marketed combinations of NSAIDs with acid-suppressing agents but uses a P-CAB instead of a PPI.